TL;DR
- 1.Hexarelin produced 140 mU/L of GH at 1 mcg/kg in a 1996 clinical trial -- the highest acute GH response recorded for any GHRP in peer-reviewed human research.
- 2.GH response drops 31% in the first 7 days of continuous daily use. By week 16 it is down 45%. But four weeks off is enough for full recovery, per the only 16-week human trial on record.
- 3.Hexarelin binds two separate receptors: GHSR1a for GH release and CD36 for cardiac protection. The heart effects survive even when the pituitary is surgically removed and GH output is zero.
- 4.WADA bans hexarelin specifically by name as 'examorelin' under S2.2. It was never nominated for FDA compounding review and was not included in the April 2026 action that cleared 12 other peptides.
- 5.Hexarelin disappeared not because of safety concerns but because its 7-day receptor ceiling made it commercially unappealing for subscription compounding models versus ipamorelin's 8-to-12-week window.
Hexarelin produced 140 mU/L of GH at 1 mcg/kg in a 1996 clinical trial. Nothing else in the GHRP class has matched that number in a peer-reviewed human study. Seven days into continuous use, the same dose produces 31% less GH. That is not a warning. That is the protocol telling you exactly when to stop.
What gets buried under the desensitization story: hexarelin works through two completely separate receptor systems. One drives GH release. The other protects your heart, and keeps working even in animals with no pituitary gland at all. Most peptide content has never mentioned the second receptor. This article covers both, plus seven other things the standard hexarelin writeup leaves out. For context on how ipamorelin and CJC-1295 compare as the more commonly available GHRPs, start there if hexarelin is new to you.
Peak GH response produced by hexarelin at 1.0 mcg/kg in healthy subjects, from the 1996 dose-response study in the Journal of Clinical Endocrinology and Metabolism. No other peptide secretagogue has produced this level of GH release in a comparable peer-reviewed human trial. The ED50 (dose producing half-maximal effect) was 0.48 mcg/kg, meaning very small amounts produce substantial GH pulses.
Among GHRPs, hexarelin is like the highest-powered engine on the market: extraordinary peak output, not built for months of continuous use. Ipamorelin is the daily-driver version: lower peak power, but you can run it for 8 to 12 weeks without the engine complaining. The question for any given person is whether you actually need peak horsepower, or whether consistent reliable output over a longer cycle matters more for your goal.
What Nobody Tells You About Hexarelin
1. The Potency Numbers Are Real, Not Marketing
Hexarelin was first tested in humans in a study published in the Journal of Clinical Endocrinology and Metabolism in 1989. Seventeen healthy men received IV hexarelin at doses from 0.25 to 2.0 mcg/kg. GH response was dose-dependent throughout: 17.8 mcg/L at the lowest dose, rising to 63.0 mcg/L at the highest. No other pituitary hormone changed. A 1996 follow-up in the same journal added the full dose-response curve: 1.0 mcg/kg produced a GH peak of 140 mU/L with an ED50 of 0.48 mcg/kg.
At the receptor level, hexarelin activates GHSR1a at roughly 1 nanomolar, compared to ghrelin's 10 nanomolar for equivalent calcium mobilization. That is a 10-fold receptor binding advantage over the endogenous ligand. No other peptide secretagogue studied in humans has matched hexarelin's acute GH ceiling in a fair peer-reviewed comparison.
One practical advantage often misattributed to GHRP-6 but not hexarelin: appetite stimulation. GHRP-6 is notorious for driving ravenous hunger within 30 minutes of dosing. Hexarelin does not. Despite binding the same receptor family, hexarelin is appetite-neutral to mildly suppressive in the clinical record. For users in a caloric deficit, that distinction matters more than the raw GH peak comparison.
2. It Punched Through Steroid-Induced Pituitary Suppression Where GHRH Could Not
A 1995 study in the Journal of Endocrinology tested hexarelin in patients on glucocorticoid therapy, a population known to have severely blunted pituitary GH response. GHRH, the natural trigger for GH release, produced a median GH delta of just 0.9 mcg/L in these subjects. That is barely a whisper of GH output.
Hexarelin alone produced 15.5 mcg/L in the same patients, statistically matching its response in healthy controls (17.9 mcg/L). The glucocorticoid-induced suppression that shut down the GHRH pathway had almost no effect on hexarelin's mechanism. If you are on long-term corticosteroids and GH axis suppression is a concern, hexarelin bypasses that bottleneck in a way GHRH analogs cannot. No other GHRP has the same documented override in a human study.
3. Desensitization Starts in 7 Days, Not 2 Weeks
The "two-week cycle" recommendation for hexarelin appears everywhere in peptide communities. The data says the receptor starts downregulating faster than that. The only 16-week human trial of hexarelin (Growth Hormone and IGF Research, 1998) tracked GH area under the curve in 12 healthy elderly subjects at regular intervals during continuous daily use.
The GH response dropped from 19.1 mcg/L*h at baseline to 13.1 mcg/L*h at the end of week 1. That is a 31% attenuation in seven days. By week 4, it reached 12.3. By week 16, it bottomed at 10.5, a total 45% below baseline. The receptor is already resisting by day 7 of continuous use, not day 14. If you are running hexarelin for "two weeks" because you read that number somewhere, you are already past the point of optimal response by the time you stop.
4. Full Recovery Happens in 4 Weeks Off, Not Months
The same 1998 trial measured GH response four weeks after stopping hexarelin. The result: 19.4 mcg/L*h, statistically indistinguishable from the pre-treatment baseline of 19.1. Full recovery. The receptor downregulation is entirely reversible and the timeline for reversal is shorter than most people assume.
"After a four-week washout period, GH area under the curve returned to 19.4 mcg/L*h, not significantly different from the pre-treatment baseline of 19.1 mcg/L*h, confirming that receptor desensitization induced by continuous hexarelin administration is fully reversible within this timeframe."
Growth Hormone and IGF Research, 1998, 16-week hexarelin trial in healthy elderly subjects
The practical protocol this data suggests: 7 to 10 days on, 4 weeks off. Not because of safety concerns, but because that is exactly when the receptor recovers per the only long-duration human trial available. For a full breakdown of how GH receptor reset timelines work across different secretagogues, see the GH receptor reset guide.
Time to full GHSR1a recovery after continuous hexarelin use, per the 1998 Growth Hormone and IGF Research 16-week human trial. The receptor downregulation is complete but reversible. This data point is the actual basis for the "4 weeks off" recommendation in hexarelin cycling protocols.
5. Hexarelin Works Through a Second Receptor That Has Nothing to Do With GH
In 2002, a paper in the Proceedings of the National Academy of Sciences identified CD36, a scavenger receptor expressed on cardiomyocytes and microvascular endothelium, as a second binding target for hexarelin. The researchers confirmed this by testing hexarelin in hypophysectomized rats, animals with their pituitary glands surgically removed and zero GH output. Hexarelin still protected these rats against ischemia-reperfusion injury. The GH axis was completely absent and the cardiac protection survived intact.
This is the buried lede in the hexarelin literature. A peptide most people know only as the strongest GHRP is simultaneously a direct cardiovascular protective agent through a scavenger receptor that has nothing to do with growth hormone. The two receptor systems are pharmacologically independent. You cannot remove one effect by blocking the other. CD36 binding also overlaps with the oxidized LDL binding site on that receptor, adding an anti-atherosclerotic dimension the community almost never discusses.
Expressed in: pituitary, hypothalamus, liver, fat tissue, peripheral tissues. Role: triggers GH pulse release from the pituitary. Hexarelin binds at 1 nanomolar (10x higher affinity than ghrelin). Desensitizes with continuous use. Key genetic variable: GHSR loss-of-function variants predict non-response.
Expressed in: heart muscle cells, vascular endothelium, macrophages, platelets. Role: mediates cardiac protection against ischemia. Reduces infarct size and interstitial fibrosis. Works independently of GH. Confirmed functional in hypophysectomized (pituitary-removed) animals. No desensitization data available for this pathway.
6. The Cardiac Data Is Actually Stronger Than the GH Data
A 2014 review in the Journal of Geriatric Cardiology quantified hexarelin's acute cardiac effects: left ventricular ejection fraction rose from 64.0% to 70.7% after a single dose (p less than 0.03). Hexarelin directly outperformed ghrelin on every cardiac endpoint measured, including LV end-diastolic pressure, coronary perfusion pressure, and creatine kinase release (a marker of cardiac cell damage).
A 2018 study in Physiological Reports pushed this further. Mice who received hexarelin for 21 days post-myocardial infarction had an ejection fraction of 49.25% versus 36.96% in untreated controls. Interstitial collagen, the scar tissue that replaces dead heart muscle, dropped 72%. Total collagen concentration fell 53%. Hexarelin was structurally remodeling cardiac tissue through a receptor that nobody knew existed when the peptide was first synthesized in the 1980s. The GH story is the one everyone talks about. The CD36 cardiac story is the one that may ultimately matter more clinically.
7. WADA Bans It Specifically by Name
WADA's 2026 Prohibited List names "examorelin (hexarelin)" explicitly under Section S2.2, Growth Hormone Secretagogues. It is banned at all times, in- and out-of-competition, as a non-specified substance carrying the maximum sanction tier. Ipamorelin and GHRP-6 are prohibited under the same section via catch-all language covering any GH secretagogue. Hexarelin gets its own named entry, which reflects both its documented potency and the fact that WADA was tracking it specifically from early clinical research.
If you compete in any WADA-governed sport, the anti-doping consequence is unambiguous. This is not a gray area or a gap in the catch-all language. Examorelin is on the list by name.
8. It Has No Legal US Compounding Pathway and Was Never Even Nominated for Review
The April 2026 FDA action removed 12 peptides from the Category 2 "do not compound" list. Hexarelin was not among them. More revealing: hexarelin was never nominated for inclusion in either the 503A or 503B bulk drug substance lists in the first place. GHRP-2, GHRP-6, and ipamorelin were all nominated, reviewed, and placed on those lists. Hexarelin bypassed that entire process by never entering it.
There is no FDA review underway for hexarelin. No compounding pharmacy has legal authorization to compound it in the US under 503A or 503B. Any US vendor selling hexarelin is doing so as "research chemical, not for human use" with no regulatory oversight of identity, purity, or sterility. For a full picture of how current FDA peptide compounding status breaks down across commonly used compounds, see the 2026 US peptide legal guide.
9. The Real Reason Nobody Uses It Is Not Safety -- It Is the Business Case
The absence of hexarelin from mainstream use is often blamed on its desensitization speed. That is part of it. But the deeper reason is commercial. Hexarelin has no sponsor. Ipamorelin made it to common clinical use because it had favorable pharmacokinetics for a stable product and enough compounding pharmacy interest to build supply chains. Hexarelin's 7-day receptor ceiling means a user cycles off every two weeks, which makes it a poor fit for subscription-model compounding businesses compared to ipamorelin's 8-to-12-week protocol windows.
A 2021 study in the Canadian Journal of Physiology and Pharmacology found that hexarelin co-administered with morphine significantly attenuated the development of opioid analgesic tolerance in rats, a GHSR-mediated effect with no ipamorelin equivalent in the published record. That angle suggests untapped clinical applications entirely separate from body composition. Nobody has pursued them commercially. Hexarelin sits in a category of highly characterized research peptides that fell out of use not because they failed, but because no entity had a business reason to push them forward.
What Hexarelin Dosage Data Actually Exists?
No FDA-approved dosing exists and no Western clinical guidelines have been established. The numbers below come from published clinical trials and community practice. They are not a dosing recommendation.
| Protocol Context | Dose | Route | Cycle Length | Source |
|---|---|---|---|---|
| Original human trials (acute) | 0.25 to 2.0 mcg/kg | Intravenous (single dose) | Single administration | JCEM, 1989 and 1996 |
| 16-week desensitization trial | 2 mcg/kg per day (approx. 150 mcg for 75 kg person) | Subcutaneous | 16 weeks then 4-week washout | GH and IGF Research, 1998 |
| Community reference range | 100 to 200 mcg per day | Subcutaneous | 7 to 10 days maximum, 4-week washout | Community protocol (no RCT basis) |
| CD36 cardiovascular research | Varied (animal models) | Intraperitoneal (animals) | 21 days in MI model | Physiological Reports, 2018 |
The key variable is cycle length, not dose. The data supports a 7-to-10-day active window based on when desensitization becomes meaningful. The community "two-week" convention is slightly too long per the 1998 trial data showing 31% attenuation by day 7.
For the genetics context on why your GHR genotype changes how much you get from any given GH pulse, see the IGF-1 receptor genetics guide. The d3-GHR variant, carried by roughly 80% of people, produces 56% more IGF-1 per GH pulse. Combined with hexarelin's stronger acute GH release, d3/d3 carriers should start below community reference doses and monitor bloodwork. See the hexarelin peptide profile for a condensed compound summary.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is hexarelin and how does it work?
Hexarelin is a synthetic hexapeptide analog of GHRP-6 that binds the ghrelin receptor (GHSR1a) to trigger GH pulse release from the pituitary. It also binds CD36, a scavenger receptor on heart muscle cells and vascular endothelium, through a completely independent mechanism. The two pathways operate separately: blocking one does not remove the other. At the GHSR1a level, hexarelin binds at roughly 1 nanomolar concentration, compared to ghrelin's 10 nanomolar, giving it roughly 10-fold higher receptor affinity than the endogenous ligand.
Is hexarelin stronger than ipamorelin?
Yes, based on the available clinical and receptor pharmacology data. The 1996 JCEM dose-response study showed hexarelin producing 140 mU/L of GH at 1 mcg/kg in healthy subjects, a number no ipamorelin trial has matched in a comparable human study. Hexarelin also broke through glucocorticoid-induced pituitary suppression where GHRH could not, producing 15.5 mcg/L in steroid-treated patients versus GHRH's 0.9 mcg/L. No published head-to-head human clinical trial directly compared hexarelin and ipamorelin at equivalent molar doses, so the strength comparison is supported by receptor pharmacology and separate trial data rather than a single direct study.
Why does hexarelin stop working after a week or two?
The ghrelin receptor (GHSR1a) downregulates with continuous stimulation. In the only 16-week human trial on hexarelin, GH response dropped 31% within the first 7 days of daily use and reached a total of 45% attenuation by week 16. This is receptor desensitization: the signaling machinery that triggers GH release becomes less responsive the longer it is continuously activated. The mechanism applies to all ghrelin-mimetic peptides (ipamorelin, GHRP-6, GHRP-2), but hexarelin's higher receptor affinity means it drives desensitization faster than the lower-affinity alternatives.
How long does it take for hexarelin receptor sensitivity to recover?
Four weeks, based on the 1998 Growth Hormone and IGF Research trial. After 16 weeks of continuous daily hexarelin, the researchers measured GH response four weeks after stopping. It returned to 19.4 mcg/L*h, statistically indistinguishable from the pre-treatment baseline of 19.1 mcg/L*h. Full recovery in four weeks. This is the evidence basis for the '4 weeks off' protocol recommendation. No equivalent long-duration washout data has been published for ipamorelin specifically.
What is hexarelin's effect on the heart?
Hexarelin binds CD36, a scavenger receptor on cardiomyocytes and vascular endothelium, and produces direct cardioprotective effects independent of its GH-releasing function. The 2002 PNAS study confirmed this by showing hexarelin protected against ischemia-reperfusion injury in hypophysectomized animals with no pituitary gland and zero GH production. A 2014 Journal of Geriatric Cardiology review found hexarelin raised left ventricular ejection fraction from 64% to 70.7% acutely. A 2018 Physiological Reports study found 21 days of post-MI hexarelin produced 49.25% EF versus 36.96% in controls, with 72% less interstitial cardiac collagen. These effects operate through CD36, not through GH or IGF-1.
Is hexarelin legal in the US?
Hexarelin has no FDA-approved compounding pathway in the US. It was never nominated for inclusion on the 503A or 503B bulk drug substance lists, which means it was not part of the FDA regulatory review process that placed GHRP-2, GHRP-6, and ipamorelin on compounding oversight lists. It was also not included in the April 2026 FDA action that removed 12 peptides from the Category 2 prohibited compounding list. Any US vendor selling hexarelin is doing so as a research chemical with no regulatory oversight of identity, purity, or sterility.
What is the recommended hexarelin dosage?
No FDA-approved or clinically established dosing exists for hexarelin. The 1998 desensitization trial used 2 mcg/kg per day subcutaneously, approximately 150 mcg for a 75 kg person. Community protocols typically reference 100 to 200 mcg per day. The most important dosing variable is cycle length, not the per-dose amount: the evidence supports a 7-to-10-day active window before receptor desensitization becomes significant, followed by a 4-week washout period based on the recovery data from the 1998 trial.
Why do peptide companies not sell hexarelin if it is the strongest GHRP?
The main barrier is commercial, not safety-related. Hexarelin's ghrelin receptor begins desensitizing within 7 days of continuous use, which means users must cycle off every 7 to 10 days with a 4-week washout. Ipamorelin can be run for 8 to 12 weeks, making it far more suitable for subscription-model compounding businesses. Additionally, hexarelin was never nominated for the FDA review process that gave ipamorelin a pathway toward legal compounding. Without a commercial sponsor willing to fund that regulatory process, hexarelin has no route toward the kind of legitimacy that drives clinical adoption.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.